Robin Swartz, the Chief Operating Officer and Chief Business Officer of Voyager Therapeutics, Inc. (NASDAQ:VYGR), recently sold 6,500 shares of the company’s common stock. The shares were sold at a weighted average price of $5.65, with prices ranging from $5.62 to $5.70, generating a total of $36,725. The transaction occurs as the $324 million market cap company trades near its 52-week low, with InvestingPro analysis suggesting the stock may be undervalued. Following this transaction, Swartz holds 112,328 shares directly. This transaction was disclosed in a filing with the Securities and Exchange Commission on December 26, 2024. Notably, Voyager maintains a strong financial position with more cash than debt on its balance sheet and a healthy current ratio of 8.45x, indicating robust liquidity. Get access to 8 more key insights and a comprehensive Pro Research Report covering VYGR through InvestingPro’s advanced analytics platform.
In other recent news, Voyager Therapeutics has been making significant strides in the field of neurological disease treatments. This is evidenced by their third-quarter 2024 financial report and recent earnings call. The company reported $24.6 million in collaboration revenue and $38.4 million in operational expenses, with a substantial cash reserve of $345.4 million, projected to fund operations into 2027.
Voyager Therapeutics recently received a Buy rating from Citi, reflecting the firm’s optimism about the company’s platform capabilities. Additionally, Oppenheimer maintained a positive outlook on Voyager and reiterated an Outperform rating, focusing on the implications of the Phase 2a TOGETHER study of bepranemab in early Alzheimer’s disease for Voyager’s anti-tau monoclonal antibody VY7523.
The company has completed enrollment for VY7523’s single ascending dose trial and plans to report initial data in the first half of 2025. Voyager is also anticipated to submit Investigational New Drug applications for its SOD1 ALS gene therapy and two partnered gene therapies in 2025. These recent developments reflect Voyager’s commitment to developing treatments for neurological diseases, with a robust pipeline of wholly-owned and partnered programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.